Gilead Sciences (NASDAQ: GILD) CEO sells 10,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences Chairman & CEO Daniel O'Day reported an open-market sale of 10,000 shares of Common Stock on 2026-03-27 at an average price of $136.8162 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on 2025-02-28, with sale prices ranging from $136.51 to $137.22. Following this sale, he continues to directly hold 642,567 shares of Gilead Sciences common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($1,368,162)
Net Sell
1 txn
Insider
O'Day Daniel Patrick
Role
Chairman & CEO
Sold
10,000 shs ($1.37M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 10,000 | $136.8162 | $1.37M |
Holdings After Transaction:
Common Stock — 642,567 shares (Direct)
Footnotes (1)
- The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Sale prices for the transactions reported range from $136.51 to $137.22. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Key Figures
Shares sold: 10,000 shares
Average sale price: $136.8162 per share
Post-sale holdings: 642,567 shares
+2 more
5 metrics
Shares sold
10,000 shares
Open-market sale of Common Stock on 2026-03-27
Average sale price
$136.8162 per share
Reported average price for 10,000-share sale
Post-sale holdings
642,567 shares
Total shares directly owned after the transaction
Sale price range
$136.51–$137.22 per share
Range of prices for reported sale transactions
Trading plan adoption date
2025-02-28
Rule 10b5-1 trading plan adoption referenced in footnote
Key Terms
Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4
4 terms
Rule 10b5-1 trading plan regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
""security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Gilead Sciences (GILD) report for Daniel O'Day?
Gilead Sciences reported that Chairman and CEO Daniel O'Day sold 10,000 shares of Common Stock. The open-market sale occurred on 2026-03-27 at an average price of $136.8162 per share, according to a Form 4 insider trading report.
What type of insider transaction did Gilead (GILD) disclose for its CEO?
The company disclosed an open-market sale of Common Stock by its Chairman and CEO. The Form 4 classifies the transaction with code "S" for sale, indicating a non-derivative disposition of 10,000 shares at an average price of $136.8162 per share.